Advisor Group Holdings, Inc. Summit Therapeutics Inc. Transaction History

Advisor Group Holdings, Inc.

$43.4 Billion
Q1 2024

A detailed history of Advisor Group Holdings, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 11,861 shares of SMMT stock, worth $85,873. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,861

Previous 143,956 91.76%

Holding current value

$85,873

Previous $375,000 86.93%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.55 - $5.07 $336,842 - $669,721	-132,095 Reduced 91.76%	11,861 $49,000
Q4 2023 Feb 12, 2024	SELL	$1.67 - $2.83 $42,788 - $72,510	-25,622 Reduced 15.11%	143,956 $375,000
Q3 2023 Nov 13, 2023	BUY	$1.54 - $2.42 $1,848 - $2,904	1,200 Added 0.71%	169,578 $317,000
Q2 2023 Aug 10, 2023	BUY	$1.32 - $2.81 $16,907 - $35,993	12,809 Added 8.23%	168,378 $422,000
Q1 2023 May 12, 2023	BUY	$1.38 - $5.41 $150,965 - $591,826	109,395 Added 236.92%	155,569 $272,000

Q4 2022 Feb 10, 2023	BUY	$0.68 - $5.31 $3,944 - $30,797	5,800 Added 14.37%	46,174 $196,000
Q3 2022 Nov 14, 2022	BUY	$0.89 - $1.63 $26,498 - $48,531	29,774 Added 280.89%	40,374 $48,000
Q2 2022 Aug 10, 2022	BUY	$0.92 - $2.38 $920 - $2,380	1,000 Added 10.42%	10,600 $11,000
Q1 2022 May 04, 2022	SELL	$2.0 - $3.45 $2,960 - $5,106	-1,480 Reduced 13.36%	9,600 $24,000
Q3 2021 Nov 05, 2021	BUY	$4.83 - $8.27 $24,633 - $42,177	5,100 Added 85.28%	11,080 $56,000
Q2 2021 Aug 02, 2021	BUY	$5.15 - $8.46 $30,797 - $50,590	5,980 New	5,980 $44,000

Others Institutions Holding SMMT

# of Institutions

107

Shares Held

41.3M

Call Options Held

103K

Put Options Held

29.9K

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $1.46B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Summit Therapeutics Inc. Transaction History